The American Journal of Managed Care

Early Data Show Promising Outcomes as CAR T-Cell Therapy Expands Beyond Academic Centers

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...
MedPage Today on MSN

CAR7 Gene Therapy Shows Promise in T-Cell ALL

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
The American Journal of Managed Care

Linking T-Cell Composition to CAR T Efficacy in Multiple Myeloma

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...
Cure Today

Revolutionizing CAR T-Cell Therapy to Improve Patient Access

CAR T-cell therapy demand is rising, prompting institutions to expand access and reduce care barriers, exemplified by Vanderbilt-Ingram Cancer Center's outpatient center. Dr. Oluwole emphasizes ...
Fred Hutch

For many blood cancer patients, CAR T-cell therapy is game-changing

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

T cells gain superior memory through new reprogramming method, boosting cancer-fighting abilities

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
Medscape

In Vivo CAR T-Cell Therapy Shows Potential in Refractory SLE

CD19 chimeric antigen receptor (CAR) T-cell therapy showed potential in treating patients with refractory systemic lupus erythematosus (SLE), with B-cell depletion and disease activity reduction ...